腫瘍学的集団におけるメタドンとQTc間隔の延長のリスクの評価
Daniel Yuwen Li1, Serena Kim2, Saba Javed3
1University of Texas McGovern Medical School, Houston, Texas, USA Daniel.Li@uth.tmc.edu.
Regional anesthesia and pain medicine
|February 17, 2026
まとめ
癌の疼痛管理におけるメタドンの使用は,12ヶ月後に小規模で統計的に有意なQTc間隔増加を示しました. 心臓併発症ではQTcがより有意に増加しましたが,ほとんどの患者は副作用を体験しませんでした.
科学分野:
- 心臓病学 心臓病学
- 腫瘍学 腫瘍学
- 薬理学 薬理学とは
背景:
- メタドンは,がんの痛みに対する一般的なオピオイドです.
- 高用量メタドンはQTc延長と関連しており,低用量がんの痛みに対する影響はあまり知られていない.
研究 の 目的:
- 疼痛管理のためにメタドンを使用しているがん患者の心血管効果,特にQTc区間の変化を評価するために.
主な方法:
- メタドンで治療を受けた492人の成人がん患者の遡及的グラフレビュー.
- ベースラインとフォローアップのEKGから人口統計,臨床データ,QTc間隔を収集した.
主要な成果:
- メタドン投与開始から≥12ヶ月後,統計的に有意なQTc増加4.36 msが観察されました.
- 心臓併発症は,9.40 ms QTc増加と関連していました.
- 全体的にQTc延長は12ヶ月後に3%から6.8%に上昇しました.
結論:
- メタドンは,がん患者でQTcが小さいが統計的に有意な増加と関連しており,開始後 ≥12ヶ月です.
- このQTcの変化は,ほとんどの患者にとって臨床的な問題を引き起こす可能性は低い.
- 癌の痛みに対するメタドン使用に対するリスク分層のアプローチが推奨され,高リスクの個人を対象としたECGモニタリングが推奨されます.
関連する概念動画
Drug Toxicity: Risk factors
27
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
27
Therapeutic Drug Monitoring: Affecting Factors
258
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
258
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
24
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
24
Therapeutic Drug Monitoring: Overview and Classification
388
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
388
Drug Dosing: Geriatric Patients
289
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
289
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
18
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
18


